๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

mTOR as a therapeutic target in patients with gastric cancer

โœ Scribed by Salah-Eddin Al-Batran; Michel Ducreux; Atsushi Ohtsu

Publisher
John Wiley and Sons
Year
2011
Tongue
French
Weight
235 KB
Volume
130
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

โœฆ Synopsis

Abstract

The poor longโ€term outcomes associated with current chemotherapy treatment of patients with advanced gastric cancer suggest a need for novel targeted agents that may confer a better survival benefit. Evidence of mammalian target of rapamycin (mTOR) activation has been demonstrated in patientโ€derived gastric cancer cells and tumors. This review explores the relevance of the mTOR pathway to gastric cancer pathogenesis and its potential as a therapeutic target in patients with gastric cancer as well as presenting the first available clinical data on mTOR inhibitors in this disease setting. Preclinical data suggest that suppression of the mTOR pathway inhibited the proliferation of gastric cancer cells and delayed tumor progression in in vitro and animal models. In the clinical setting, the mTOR inhibitor everolimus has been active and well tolerated in phase I/II studies of patients with chemotherapyโ€refractory metastatic gastric cancer. Based on these promising results, everolimus currently is being investigated as a monotherapy or in combination with chemotherapeutic agents in ongoing phase II/III clinical studies.

๐Ÿ“œ SIMILAR VOLUMES

Targeting mitochondria as a therapeutic
Targeting mitochondria as a therapeutic target in cancer
โœ Charles E. Wenner ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 367 KB ๐Ÿ‘ 1 views

## Abstract Knowledge of reโ€programming in cancer cells with metabolic differences from their normal counterparts has resulted in new examination of therapeutic approaches. Several studies of the role of tumor mitochondria in cancer have led to the development of nonโ€genotoxic therapies which targe

Optimizing targeted therapeutic developm
Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation
โœ Jeanne Tie; Peter Gibbs; Lara Lipton; Michael Christie; Robert N. Jorissen; Anto ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 387 KB ๐Ÿ‘ 1 views

## Abstract BRAF^__V600E__^ mutations are found in 10% of colorectal cancers (CRCs). The low frequency of this mutation therefore makes it a challenging target for drug development, unless subsets of patients with higher rates of BRAF^__V600E__^ can be defined. Knowledge of the concordance between